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Abstract
Background: Interaction of the small peptide hormone glucagon with glucagon receptor (GCGR) stimulates the
release of glucose from the hepatic cells during fasting; hence GCGR performs a significant function in glucose
homeostasis. Inhibiting the interaction between glucagon and its receptor has been reported to control hepatic
glucose overproduction and thus GCGR has evolved as an attractive therapeutic target for the treatment of type II
diabetes mellitus.
Results: In the present study, a large library of natural compounds was screened against 7 transmembrane domain
of GCGR to identify novel therapeutic molecules that can inhibit the binding of glucagon with GCGR. Molecular
dynamics simulations were performed to study the dynamic behaviour of the docked complexes and the
molecular interactions between the screened compounds and the ligand binding residues of GCGR were analysed
in detail. The top scoring compounds were also compared with already documented GCGR inhibitors- MK-0893
and LY2409021 for their binding affinity and other ADME properties. Finally, we have reported two natural drug
like compounds PIB and CAA which showed good binding affinity for GCGR and are potent inhibitor of its
functional activity.
Conclusion: This study contributes evidence for application of these compounds as prospective small ligand
molecules against type II diabetes. Novel natural drug like inhibitors against the 7 transmembrane domain of GCGR
have been identified which showed high binding affinity and potent inhibition of GCGR
Background
Diabetes mellitus comprises a group of metabolic dis-
eases which are rapidly growing worldwide. It has so far
affected approximately 347 million people globally [1].
Glucagon receptor (GCGR) is an affiliate of secretin-like
(class B) family of G-protein-coupled receptors (GPCRs)
in humans [2]. Secretin-like GPCRs contain a globular
N-terminal extracellular domain (ECD) defined by three
conserved disulphide bonds [3,4] and a 7 transmembrane
(7 TM) domain. GCGR is activated by a 29 amino acid
long peptide hormone, Glucagon, which is secreted by
pancreatic a-cells in response to decreased circulating
blood glucose levels. GCGR helps in maintaining glucose
homeostasis by increasing hepatic gluconeogenesis and
glycogenolysis [5]. Binding of glucagon to GCGR acti-
vates signal transduction pathway leading to the activa-
tion of adenylate cyclase. This triggers the production of
cAMP which activates the protein kinase A, that finally
results in an increase in blood glucose levels [6]. In type
2 diabetes mellitus, increase in the level of glucagon
secretion takes place in both the fasting and postprandial
state caused due to either impaired pancreatic a-cell sen-
sing, or lack of suitable a-cell response to insulin [5]. It
has been reported that glucagon receptor knockout in
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mice prevents the deadly metabolic and clinical phenotype
of type 1 diabetes [7]. The inhibition of glucagon-GCGR
interaction has been reported to control the hepatic glu-
cose overproduction that makes it an attractive therapeutic
strategy for the treatment of type II diabetes mellitus.
Most of the available glucagon receptor based inhibitors
for the treatment of type 2 diabetes mellitus fall in the
category of glucagon neutralizing antibodies [8,9] or small
molecular weight glucagon receptor antagonists [10-15]
which have been shown to efficiently terminate glucagon
receptor action. A new glucagon receptor antisense oligo-
nucleotides was developed as potential therapeutic agent
for type 2 diabetes mellitus [16]. In spite of the above
advances, there are concerns corresponding to safety, tol-
erability and stimulation of adverse immune responses
with the above mentioned agents to reduce glucagon
receptor signalling. In view of these concerns, glucagon
receptor antagonists of natural origin may offer a favour-
able therapeutic option helping the patients attain a proper
glycemic control and to evade the long-standing obstacles
related with this disease.
Due to the lack of crystal structure of class B 7 TM
domains, discovery of clinically functional small molecule
glucagon receptor antagonists was difficult. Till date few
GCGR-ligand binding models have been proposed which
are based on the approach of site-directed mutagenesis
[17-19], photo-crosslinking [20-22], and modelled struc-
ture-based virtual screening studies [23]. However with
the recent elucidation of the crystal structure of 7 TM
domain of glucagon receptor, a rational drug design
approach can be applied for identification of potent agents
against type 2 diabetes [24].
In the present study, we have identified novel natural
GCGR antagonists based on the GCGR 7 TM domain
crystal structure. The inhibition of glucagon receptor
results in overall glycemic control and improved glucose
tolerance. A large virtual database of natural compounds
was screened against the high resolution crystal structure
of GCGR using high throughput virtual screening
approach. In silico screening led to the identification of a
new class of GCGR inhibitors that hinder the GCGR-glu-
cagon interaction. The molecular dynamics (MD) of the
complexes were then simulated to elucidate the dynamic
behaviour of molecular interactions between the screened
compounds and the functional residues of GCGR. This
study smoothens the path for the development of novel
leads possessing improved binding properties, high drug
likeness and low toxicity to humans for type 2 diabetes
mellitus treatment.
Methods
Protein and ligand library preparation
The crystal structure of human glucagon receptor [PDB
ID: 4L6R], determined at a resolution of 3.40 Å, was
retrieved from the Protein Data Bank [24]. GCGR
contains a 7 TM helical domain. The retrieved structure
was processed using the Protein Preparation Wizard in
Schrodinger’s Maestro interface [25] to prepare it for
docking studies. It involved addition and optimization of
hydrogen bonds, removal of bad contacts, optimization
of bond lengths, creation of disulfide bonds, capping of
protein terminals, conversion of selenomethionine to
methionine and fixing of missing residues. The prepared
structure was then optimized to acquire an energetically
stable geometry [26]. A virtual ligand library was pre-
pared by extracting proximately 1,69,109 natural com-
pounds from the ZINC database [27] and processing
them with Schrodinger’s LigPrep Wizard [28]. Further,
maximum possible tautomeric, stereochemical and ioni-
zation variants of these molecules were generated.
Grid generation, high throughput virtual screening and
extra precision docking studies
As suggested by GCGR-glucagon binding model, Trp 36,
Gln 142, Tyr 138, Tyr 149, Val 191, Gln 232, Glu 362, Leu
386, Trp 295 and Asn 298 residues of GCGR are directly
involved in binding with glucagon [20]. A grid was gener-
ated in the region of these functional residues of prepared
protein by means of the receptor grid generation utility of
the Glide docking module of the Schrodinger suite [29,30].
For screening of prepared libraries Glide program was
applied [29,31]. Glide algorithm is derived from a systematic
method for virtual screening with incremental construction
searching and provides the output as the G-Score scoring
function combined with a range of other parameters [32].
The screening against 7 TM domain of GCGR at the essen-
tial grid coordinates was initially performed with the HTVS
docking algorithm [29]. Compounds with a significant dock-
ing score were then, subjected to Glide XP, a more accurate
docking algorithm for further refined screening [28].
Molecular dynamics simulations of docked complexes
In order to examine the stability of top scoring compounds
molecular dynamics simulations were performed using
Desmond Molecular Dynamic System [33] with Optimized
Potentials for Liquid Simulations (OPLS) all-atom force
field 2005 [34]. The protein-ligand complexes obtained
from Glide’s XP docking protocol were prepared using
Desmond set-up wizard. All the missing residues were rec-
tified manually. The system, thus obtained was solvated in
a triclinical periodic box of SPC water and neutralized with
suitable number of counter-ions. The distance between
box wall and protein-ligand complex was set to greater
than 10 Å so that the complex does not directly interact
with its own periodic image. Energy minimization of the
prepared system was done up to a maximum of 10 steps
using steepest descent method or until a gradient threshold
(25 kcal/mol/Å) was obtained. Desmond’s default protocol
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was applied to equilibrate the system. The details of the
relaxation protocol used for equilibration and minimization
steps are given in additional file 1. MD simulations were
performed on this equilibrated system for a time period of
20 ns at 300 K constant temperature and 1atm constant
pressure using a time step of 2 fs. Throughout the simula-
tions process, smooth particle Mesh-Ewald method was
used to calculate long range electrostatic interactions. A 9
Å radius cut-off was set for coulombic short range interac-
tion cutoff method. At every 4.8 ps time step, frames were
captured to form trajectory. The configuration file used for
simulation process is given in additional file 2.
The root mean square deviation (RMSD) of the pro-
tein-ligand complex was calculated for the entire simu-
lations trajectory in reference to the first frame. Ligplot
program was used for the calculation of hydrogen bonds
and other non-bonded interactions [35].
Comparison of the proposed natural compounds with
some already documented GCGR antagonists
Several compounds have been developed by various groups
with inhibitory activity against glucagon receptor for the
treatment of type II diabetes mellitus. Recently, MK-0893
(Merck) [36] and LY2409021 (Eli Lilly) [37] have been
reported with GCGR inhibitory activity supported with
clinical data. The 3D structure of MK-0893 was retrieved
from PubChem database. The structure of LY2409021 was
prepared in 3D sdf format using Marvin sketch. These two
compounds were further prepared using LigPrep to look
for different possible conformations. The compounds were
then docked against the GCGR structure using the same
grid coordinates generated around the catalytically active
residues of the GCGR receptor.
Prediction of pharmacokinetics of CAA and PIB in human
body and comparison of the results with the already
known antagonists
Certain structural and molecular features of compounds
govern their pharmacokinetic properties in our body.
Qikprop module of Schrodinger [38] was used to evalu-
ated the drug likeliness of all the four inhibitors. The
obtained values for molecular weight, number of hydrogen
bond donors, number of hydrogen bond acceptors and
logP were used to assess violation of Lipinski’s rule of five
if any. To further account for the potential of the com-
pounds to act as efficient drug candidates, their absorp-
tion, distribution, metabolism and excretion (ADME)
properties were also calculated in silico using Qikprop.
Results and discussion
Outcomes of high throughput virtual screening and
docking studies
Human GCGR, one of the most promising drug targets
for treatment of type II diabetes mellitus, was virtually
screened against approximately 0.2 million natural com-
pounds, a special subset of ZINC database. The screened
compounds were ranked according to their binding affi-
nity, calculated as the scoring function called the GlideG-
Score. Of all the compounds that were identified from
HTVS, those with a Glide score of less than −6.0 (64 com-
pounds) were subjected to the Glide XP docking protocol.
Among the top 10 scoring compounds 2 compounds
which were fulfilling the Lipinski’s filter criteria were cho-
sen for further studies and their properties are listed in
Table 1. The values of the other important docking para-
meters like ligand efficiency score, glide emodel score etc.
used for evaluating the selection criteria of the top-




PIB) had a Glide score of −9.47 kcal/mol, while the
second compound 2-(2-(4,8-dimethyl-7-((3-methylbut-
2-en-1-yl)oxy)-2-oxo-2H-chromen-3-yl) acetamido)acetic
acid (ZINC06623951;CAA) had a score of −9.53 kcal/
mol. Both the compounds had good binding affinity
for the GCGR receptor. Their chemical structure is
given in Figure 1. The results revealed that both the
Table 1 Values of various physico-chemical descriptors.
Descriptors CAA PIB MK-0893 LY2409021 Recommended range
#star 0 0 4 0 0-5
Molecular weight 373.405 498.968 588.489 294.35 <500
Hydrogen bond donors 1.25 1 4.25 1 <5
Hydrogen bond acceptors 7 5 5.25 5.5 <10
logP 2.618 5.485 8.18 -1.062 <5
SASA 707.226 652.412 900.01 594.833 300-1000
Oral absorption 64.462 100 85.123 28.784 >80% high
<25% poor
CNS activity 0 -2 -2 -2 -2 inactive
2 active
Blood brain barrier partition coefficient -2.063 -0.317 -1.179 -1.8 -3.0-1.2
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compounds, PIB and CAA, were interacting with the
important glucagon binding residues of GCGR by
hydrogen bond and hydrophobic interactions (Table 3).
Binding mode analysis of ligand-docked GCGR complexes
GCGR-PIB Complex
GCGR is a class B G protein coupled receptor where
7 TM helices create a deep and wide cavity for ligand
binding. In the case of the GCGR-PIB complex, PIB inter-
acted with the glucagon binding residues of GCGR with
the formation of 2 hydrogen bonds and a number of
hydrophobic and van der Waal contacts. Tyr145 and
Trp295 were the two residues involved in hydrogen bond
formation (Figure 2A). The H atom of OH group of
amino acid Tyr145 was forming hydrogen bond (3.28 Å)
with the N1 atom of PIB. Second hydrogen bond (3.08 Å)
was formed by atom O3 of PIB with the NE1 atom of
GCGR residue Trp295. In addition, Gln232, Asn298,
Phe365, Gln142, Leu386, Asp195, Val191 and Tyr149 resi-
dues of GCGR were involved in hydrophobic and van der
Waal interactions in the GCGR-PIB complex (Figure 2B).
Among all these interacting residues, Trp295, Asn298 and
Gln142 have been shown to directly interact with glucagon
while mutation in Tyr145, Asp195 and Leu386 has been
shown to decrease the glucagon binding. Tyr149, Gln232,
Val191 and Glu109 are among the other residues that line
the binding pocket of the GCGR. These are all crucial
amino acids and play a prominent role in binding of gluca-
gon with GCGR. PIB binding to these residues can thus
prevent interaction between glucagon and GCGR thereby
inhibiting the downstream signal transduction pathway. A
variety of physicochemical properties of PIB were also
considered which corroborate its drug like characteristics
(Table 1).
GCGR-CAA complex
CAA is a small compound with a molecular weight of
372.29 g/mol and lipophilicity value (logP) of 2.618 at pH
7. CAA formed 3 hydrogen bonds and numerous hydro-
phobic interactions with human GCGR. As illustrated in
Figure 2C, 2 hydrogen bonds were formed between the
OG atom of Ser389 and the O6 & N1 atom of CAA with
bond length 2.54Å and 3.19Å, respectively, while one more
Table 2 Binding affinity scores and energies of GCGR in complex with PIB and CAA.
Compound Zinc ID Docking Score Glide Ligand Efficiency Glide evdw (kcal/mol) Glide emodel Glide energy (kcal/mol)
PIB ZINC06623951 -9.53 -1.06 -31.69 -52.56 -39.41
CAA ZINC12864028 -9.47 -0.87 -35.75 -54.20 -38.82
MK-0893 - -11.03 -0.27 -34.77 -67.70 -46.01
Ly2409021 - -5.61 -0.27 -24.37 -32.40 -32.24
Figure 1 Chemical structure of (A) CAA and (B) PIB.
Table 3 Molecular interactions displayed in pre- and post-MD simulated PIB-bound GCGR complexes.
GCGR-
Ligand












Gln232, Thr296, Asn298, Phe365, Met231, Leu307, Ile235, Phe383, Phe303, Gln142, Leu386,
Asp195, Val191, Ser389, Tyr149
PIB
Post-MD












Ser389 2.89 Lys187, Tyr133, Trp295, Leu370, Gln142, Ile235, Val191, Leu198, Leu382, Met231, Ile194,
Gly362, Asp385
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bond was formed with the NE2 atom of the neighbouring
residue Gln392 and O6 atoms of CAA with bond length
of 3.15 Å. However, several residues like Lys187, Leu386,
Glu362, Phe365, Trp295, Leu198, Tyr149, Tyr145,
Val191, and Ile194 important for ligand binding were
involved in making hydrophobic and van der Waal con-
tacts with CAA (Figure 2D). These interactions of CAA
with the crucial functional residues of GCGR suggest it to
be a promising ligand that could abolish the binding of
glucagon with GCGR.
Molecular dynamics simulations of ligand-bound GCGR
complexes
For further refinement and stabilization of both the
docked complexes, molecular dynamics simulation was
carried out for GCGR in complex with the compounds
for 20 ns using Desmond. The simulation length of 20
ns used in the study was sufficient enough to permit
reorganization of the side chains of ligand-complexed
protein thereby allowing it to acquire the energetically
most stable binding conformation.
Interaction analysis of MD-stabilized GCGR-PIB complex
To study the dynamic nature of interactions, molecular
dynamics simulation was carried out for GCGR in com-
plex with PIB for 20 ns. The frames were captured after
every 4.8 ps during the simulation run. RMSD of the pro-
tein backbone in each frame in reference to the first frame
was plotted against the simulation run time. The backbone
of the protein in the complex deviated upto 6 Å in the first
3 ns after which it acquired an almost stable conformation
which then persisted till the end of the simulation period
(Figure 3A). A structure was obtained by averaging the
coordinates of all the frames in the most stable time
frame, which was then used for further analysis. Even
though a slight shift was observed in the binding mode of
PIB, it was still occupying the cavity found within the
7TM domain of GCGR, the active cleft where glucagon
interacts with GCGR. The superimposition of the ligand
PIB in the pre- and post-MD simulated complex struc-
tures inside the ligand binding site of GCGR is depicted in
Figure 3B. A comparative analysis of the interaction pro-
files of GCGR-PIB complex before and after the MD
simulations is described in Table 3. Because of the change
in the orientation of PIB, a difference was observed in
binding pattern with GCGR. The 2 hydrogen bonds with
the residues Tyr145 and Trp295 formed subsequent to
docking were lost and a new hydrogen bond with amino
acid Val364 came into existence (Figure 3C). Val364 is a
conserved residue found in all class B GPCR’s and is also
involved in ligand binding [39]. Post simulation, PIB was
found forming hydrophobic interactions and van der Waal
contacts with various residues as mentioned in Table 3
while interaction with only those residues participating in
glucagon binding are shown in Figure 3D.
Interaction analysis of the GCGR-CAA complex post MD
simulation
Again to mimic the bodily conditions, a 20 ns long MD
simulation was carried out for GCGR in complex with
Figure 2 Molecular interactions between GCGR and screened ligands before MD simulations. (A) Pre-MD Hydrogen bond interactions in
GCGR-PIB complex. (B) Pre-MD Hydrophobic interactions between GCGR and PIB (C) Pre-MD Hydrogen bond interactions in GCGR-CAA complex.
(D) Post-MD Hydrophobic interactions between GCGR and CAA.
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CAA. The backbone of protein in complex deviated
about 6 Å in the first 10 ns after which a stable trajec-
tory was observed. The newly attained conformation
was more stable and thus persisted till the end of simu-
lation without undergoing considerable change (Figure
4A). A shift was observed in the position of the docked
ligand. The complexes obtained after molecular docking
and MD simulation were superimposed to perceive the
deviation in the conformation of CAA (Figure 4B). An
average representative structure of complex was com-
puted for the most stable time period (14-20 ns) of the
simulation to study the molecular interaction pattern. A
significant change in the H-bond interaction pattern was
observed during the simulation run. Only the H-bond
formed by CAA with Ser 389 of GCGR remained con-
served (Figure 4C). The residues of GCGR which were
involved in other non-bonded interactions with CAA
now included Lys187, Tyr133, Trp295, Leu370, Gln142,
Ile235, Val191, Leu198, Leu382, Met231, Ile194, Gly362
and Asp385 (Figure 4D). Many of these residues are
involved in direct binding with glucagon or indirectly
affect the conformation of ligand binding pocket. Inter-
action with these residues will restrict the binding of
glucagon with GCGR and down modulate the function-
ality of the receptor by deterring the downstream signal-
ling process. Therefore, we propose CAA as another
prospective candidate for GCGR inhibition.
Comparison of CAA and PIB with already documented
antagonists of GCGR
The Glide docking score of MK-0893 and LY2409021 was
compared with that of the proposed lead candidates.
Table 2 lists the glide XP docking score of CAA, PIB and
these two known GCGR inhibitors used in this study. MK-
0893 with a score of -11.03 showed much higher affinity
for GCGR in comparison to CAA and PIB whereas
LY2409021 came out to be a weak candidate with much
lower binding affinity (glide docking score = -5.60). The
Figure 3 (A) RMSD trajectory of GCGR in complex with PIB over the 20 ns simulation run. (B) Change in orientation of PIB after simulation
(red-post MD, blue-pre MD). (C) Hydrogen bond interactions between PIB and GCGR after MD simulations. (D) Hydrophobic contacts found in
GCGR-PIB complex post MD simulation.
Figure 4 (A) RMSD trajectory of GCGR protein backbone when complexed with CAA over the 20 ns simulation run. (B) Position of CAA
in GCGR active cavity before and after simulation (red-post MD, blue-pre MD). (C) Hydrogen bond interactions between CAA and GCGR after
MD simulations. (D) Hydrophobic interactions found in GCGR-CAA complex post MD simulation.
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other glide parameters also followed the similar trend
(table 2), indicating MK-0893 to be the best binder fol-
lowed by PIB, CAA and then Ly2409021. Other physico-
chemical properties of these compounds were also studied
to further explore the potential of these compounds as
drug candidates.
Physico-chemical properties and pharmacokinetics of
GCGR inhibitors- CAA, PIB, MK-0893, LY2409021
To supplement the information gained from binding
affinity prediction, Qikprop was used to calculate var-
ious other physically significant descriptors and pharma-
ceutically relevant properties of these small molecules.
Qikprop predicts these molecular properties and pro-
vides significant ranges for comparing their values with
those of 95% of already known pharmaceutical drugs.
The descriptor, “#star” denotes the number of outlying
properties of the molecule i.e., the properties which do
not fall within the range of values for already known
drugs. So, lesser the number better is the druglikeness
of the small molecule. MK-0893, which showed the
highest binding affinity, had a #star value of 4 whereas
all the other three compounds had 0 #star. Hence,
except for MK-0893, the computed properties for the
other three compounds did not lie outside the required
range and were very similar to that of the known drugs.
Lipinski’s rule of five is a thumb rule which determines
the likeliness of a drug to be orally active based on four
molecular properties. Table 1 lists the values of all four
properties for these four compounds. MK-0893 with a
molecular weight of 588.48 and logP value of 8.18 was
not satisfying the lipinski’s rule (molecular weight < 500,
no. of hydrogen bond donors < 5, no. of hydrogen bond
acceptors < 10, logP < 5). Solvent accessible surface area
(SASA) and especially polar surface area (PSA) dictate
the passive transport of molecules through membranes
thereby giving an estimate about the transport proper-
ties of the drugs. The total SASA for MK-0893, CAA,
PIB and LY2409021 was well within the range given by
QikProp. Using some knowledge based set of rules Qik-
prop also calculates the percentage probability of the
drug getting orally absorbed in the human body. This
value has been shown to correlate well with the human
oral absorption. PIB showed the highest oral absorption
with a percentage value of 100%. Out of rest three,
LY2409021 had the least value of 28.78 %. Central ner-
vous system activity is another parameter that needs to
be considered for assessing the safety issue. CAA was
found to be highly CNS inactive whereas PIB was pre-
dicted to possess some minimal amount of CNS activity.
Blood brain barrier (BBB) separates the human brain
from the direct contact of circulatory system, thus pro-
tecting the brain for unwanted solute particles. Both the
predicted compounds were shown to be BBB negative
ensuring their administration safe for the brain.
Even though MK-0893 had higher affinity for GCGR,
CAA and PIB were found to be better than this known
inhibitor in many aspects. The new compounds showed
better druglikeness with acceptable values of ADME
properties. This clearly delineates the distinctive potential
of CAA and PIB as prospective lead inhibitors of GCGR
for the treatment of type II diabetes mellitus.
Conclusion
Human glucagon receptor has an important role in glu-
cose homeostasis. Its activity can be regulated to treat type
II diabetes mellitus. Some of the known GCGR antagonists
have been found to be lipophilic molecules, with relatively
high molecular weight, making them unfit for clinical use.
With the intention to develop safe compounds with accep-
table biopharmaceutical properties, we have proposed two
novel inhibitors of natural origin for human glucagon
receptor. This study provides evidence for consideration of
these compounds as prospective small ligand molecules
for inhibition of glucagon receptor.
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